Ontology highlight
ABSTRACT: Purpose
We evaluated the outcomes of decitabine as first-line treatment in older patients with acute myeloid leukemia (AML) and investigated the predictors, including a baseline mini nutritional assessment short form (MNA-SF) score, of response and survival.Patients and methods
Between 2010 and 2018, 96 AML patients aged 65 and above who received decitabine treatment at 6 centers in Korea were retrospectively evaluated. Response rates, hematologic improvements (HI), progression-free survival (PFS), and overall survival (OS) were analyzed.Results
The median age at diagnosis was 73.9 years, and the median number of decitabine treatments administered to the patients was 4 (range, 1-29). Of 85 patients, 15 patients (17.6%) achieved complete remission (CR) or CR with incomplete blood count recovery. Twelve patients (14.1%) showed partial remission (PR), and 18 (21.2%) demonstrated HI without an objective response. The median PFS and OS were 7.0 (95% confidence interval [CI], 4.9-9.0) and 10.6 (95% CI, 7.7-13.5%) months, respectively. In multivariate analyses, MNA-SF score ≥ 8 and the absence of peripheral blood (PB) blasts were significant predictors for improved PFS and OS.Conclusions
For older patients with newly diagnosed AML, a high MNA-SF score and the absence of PB blasts were independently associated with improved survival.
SUBMITTER: Yoo KH
PROVIDER: S-EPMC7410295 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Yoo Kwai Han KH Cho Jinhyun J Han Boram B Kim Se Hyung SH Shin Dong-Yeop DY Hong Junshik J Kim Hawk H Kim Hyo Jung HJ Zang Dae Young DY Yoon Sung-Soo SS Jin Jong-Youl JY Lee Jae Hoon JH Hong Dae-Sik DS Park Seong Kyu SK
PloS one 20200806 8
<h4>Purpose</h4>We evaluated the outcomes of decitabine as first-line treatment in older patients with acute myeloid leukemia (AML) and investigated the predictors, including a baseline mini nutritional assessment short form (MNA-SF) score, of response and survival.<h4>Patients and methods</h4>Between 2010 and 2018, 96 AML patients aged 65 and above who received decitabine treatment at 6 centers in Korea were retrospectively evaluated. Response rates, hematologic improvements (HI), progression-f ...[more]